三种含铂类化疗方案治疗晚期非小细胞肺癌的疗效和药物经济学分析  

Efficacy and pharmacoeconomical analysis of three platinum based chemotherapy regimens for advanced non small cell lung cancer

作　　者：张梦希[1] 于文军[2] 任春玲 矫正[1] 安志洁[2] 王大志[1] 

机构地区：[1]青岛市市立医院药学部,山东省青岛266011 [2]青岛市市立医院肿瘤科,山东省青岛266011 [3]青岛市妇女儿童医院,山东省青岛266071

出　　处：《中国基层医药》2017年第14期2088-2091,共4页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的 观察三种含铂类联合化疗方案治疗非小细胞肺癌（NSCLC）的临床疗效及药物经济学效果.方法 采用回溯法筛选100例NSCLC患者的临床资料,按化疗方案不同分为三组,Ⅰ组35例采用NP方案（长春瑞滨＋顺铂）,Ⅱ组33例采用GP方案（吉西他滨＋顺铂）,Ⅲ组32例采用TP方案（多西他赛＋顺铂）,比较三组临床疗效、不良反应、成本效果比.结果 Ⅰ组、Ⅱ组、Ⅲ组有效率分别为31.43%、36.36%、37.50%,组间差异无统计学意义（P〉0.05）.三组不良反应主要表现为粒细胞减少、消化道反应和口腔黏膜炎,患者的耐受性良好,组间差异无统计学意义（P〉0.05）.Ⅰ组、Ⅱ组、Ⅲ组成本效果比分别为550.22元、556.48元、583.23元,Ⅰ组（NP方案）总成本最少.结论 含铂类联合化疗方案中,NP方案疗效稳定,总成本最低,最具药物经济学意义.Objective To explore the cost-effectiveness and clinical effect of three platinum based chemotherapy regiments for advanced non small cell lung cancer （NSCLC）.Methods 100 patients who were diagnosed as NSCLC,were randomly divided into four groups.The group Ⅰ received NP which was given NVB and DDP.The group Ⅱreceived GP which was given GEM and DDP.The group Ⅲ received TP which was given taxotere and DDP.The clinical effect,adverse reaction and cost effectiveness of the three groups were assessed.Results The clinical effective rates of the three groups were 31.43%,36.36%,37.50% from Ⅰ to Ⅲ group.The adverse events of the group Ⅰ and group Ⅱ were more than those of the group Ⅲ.In the adverse effects of treatment,the major cytotoxicity was digestive reaction and leukopenia in the two groups,but they were tolerable.The ratios of cost effectiveness in the four groups were 550.22yuan,556.48yuan,583.23yuan from Ⅰ to Ⅲ group.Conclusion The NP group is the best one in total cost.

关 键 词：癌 非小细胞肺 顺铂 抗肿瘤联合化疗方案 经济学 药学 

分 类 号：R734.2[医药卫生—肿瘤]